Casdin Capital, LLC
Long book
$1.32B
Q1 2026
Positions
40
Top-10 weight
77%
concentration
Last quarter
+49.5%
SPY +14.8%
Turnover
34%
of book per quarter
Strategy in plain words
auto-generated from filingsCasdin Capital, LLC is a concentrated fundamental stock-picker, specialised in healthcare (99% of the long book), running a $1.32B US long book across 40 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: REVOLUTION MEDICINES INC, GENEDX HOLDINGS CORP, RELAY THERAPEUTICS INC, BIOLIFE SOLUTIONS INC, STANDARD BIOTOOLS INC.
Over the last 9 quarters its long book ran on average 4pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+4.0%
Q2 2024
+10.1%
Q3 2024
+1.6%
Q4 2024
-19.0%
Q1 2025
+1.3%
Q2 2025
+21.0%
Q3 2025
+25.3%
Q4 2025
-17.1%
Q1 2026
+49.5%
Sector allocation
Healthcare 99%
Technology 1%
Materials 0%
Long book by quarter
What does Casdin Capital, own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| RVMD REVOLUTION MEDICINES INC | Healthcare | 2.6M | $250.6M | 19.0% | Held |
| WGS GENEDX HOLDINGS CORP | Healthcare | 3.0M | $193.1M | 14.6% | Held |
| RLAY RELAY THERAPEUTICS INC | Healthcare | 14.4M | $143.5M | 10.9% | +10.9% |
| BLFS BIOLIFE SOLUTIONS INC | Healthcare | 6.0M | $113.7M | 8.6% | Held |
| LAB STANDARD BIOTOOLS INC | Healthcare | 88.8M | $81.6M | 6.2% | Held |
| ILMN ILLUMINA INC | Healthcare | 530.0K | $65.3M | 4.9% | -11.7% |
| TXG 10X GENOMICS INC-CLASS A | Healthcare | 2.3M | $48.3M | 3.7% | +62.5% |
| DNLI DENALI THERAPEUTICS INC | Healthcare | 1.8M | $35.3M | 2.7% | Held |
| BEAM BEAM THERAPEUTICS INC | Healthcare | 1.4M | $32.2M | 2.4% | -15.6% |
| GH GUARDANT HEALTH INC | Healthcare | 315.0K | $29.1M | 2.2% | -17.1% |
| NGNE NEUROGENE INC | Healthcare | 1.4M | $28.6M | 2.2% | +9.6% |
| ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 75.0K | $24.8M | 1.9% | Held |
| MAZE MAZE THERAPEUTICS INC | Healthcare | 758.9K | $22.7M | 1.7% | Held |
| SRRK SCHOLAR ROCK HOLDING CORP | Healthcare | 350.0K | $17.2M | 1.3% | +34.6% |
| HIMS HIMS & HERS HEALTH INC | Healthcare | 700.0K | $14.5M | 1.1% | +81.8% |
| TSHA TAYSHA GENE THERAPIES INC | Healthcare | 3.3M | $14.5M | 1.1% | +116.7% |
| QGEN QIAGEN N.V. | Healthcare | 360.0K | $14.4M | 1.1% | New |
| TEM TEMPUS AI INC-CL A | Technology | 294.1K | $13.3M | 1.0% | Held |
| SEPN SEPTERNA INC | Healthcare | 553.3K | $13.3M | 1.0% | Held |
| GRAL GRAIL INC | Healthcare | 230.0K | $11.9M | 0.9% | New |
| PRME PRIME MEDICINE INC | Healthcare | 3.2M | $11.0M | 0.8% | Held |
| PSNL PERSONALIS INC | Healthcare | 1.6M | $10.2M | 0.8% | New |
| DGX QUEST DIAGNOSTICS INC | Healthcare | 50.0K | $9.8M | 0.7% | Held |
| VCYT VERACYTE INC | Healthcare | 276.3K | $8.9M | 0.7% | Held |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 450.0K | $8.4M | 0.6% | New |
| NTLA INTELLIA THERAPEUTICS INC | Materials | 355.0K | $4.6M | 0.3% | New |
| IRON DISC MEDICINE INC | Healthcare | 65.0K | $4.2M | 0.3% | New |
| MRNA MODERNA INC | Healthcare | 75.0K | $3.8M | 0.3% | New |
| GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 186.0K | $3.1M | 0.2% | +116.3% |
| ABSI ABSCI CORP | Healthcare | 973.3K | $2.9M | 0.2% | Held |
| IPSC CENTURY THERAPEUTICS INC | Healthcare | 1.2M | $2.8M | 0.2% | Held |
| BBOT BRIDGEBIO ONCOLOGY THERAPEUT | Healthcare | 282.3K | $2.5M | 0.2% | Held |
| CTNM CONTINEUM THERAPEUTICS INC-A | Healthcare | 148.3K | $1.9M | 0.1% | Held |
| PACB PACIFIC BIOSCIENCES OF CALIF | Healthcare | 723.8K | $955K | 0.1% | -82.9% |
| RXRX RECURSION PHARMACEUTICALS-A | Healthcare | 165.3K | $508K | 0.0% | Held |
| TNYA TENAYA THERAPEUTICS INC | Healthcare | 362.0K | $251K | 0.0% | Held |
| DNA GINKGO BIOWORKS HOLDINGS INC | Healthcare | 36.5K | $224K | 0.0% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 40 | $1.32B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 38 | $1.61B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 32 | $1.20B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 33 | $1.10B | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 44 | $1.22B | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 39 | $1.50B | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 35 | $1.50B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR/ARESTATEMENT | Oct 18, 2024 | 38 | $1.31B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 38 | $1.30B | SEC ↗ | |
| Q1 2024 | 13F-HR | May 15, 2024 | 37 | $1.35B | canonical | SEC ↗ |